![Sabarni Sarker](https://profiles-cardiff.imgix.net/attachments/6603?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Trosolwyg
Rwy'n fyfyriwr PhD yn yr Ysgol Fferylliaeth a Gwyddorau Fferyllol. Fy diben presennol o ymchwil yw creu system gyflenwi newydd ar gyfer cyflenwi cyffuriau lleol i'r ceudod adrannol glioblastoma.
Cyhoeddiad
2024
- Anik, A. H., Proma, F. A., Saha, P. and Sarker, S. 2024. Tegoprazan as a new remedy for gastrointestinal diseases in comparison with its therapeutic predecessors: A mini-review. Current Drug Research Reviews 16(1), pp. 11-17. (10.2174/2589977515666230428140741)
2021
- Sarker, J., Das, P., Sarker, S., Roy, A. K. and Momen, A. Z. M. R. 2021. A review on expression, pathological roles, and inhibition of TMPRSS2, the serine protease responsible for SARS-CoV-2 spike protein activation. Scientifica 2021(1) (10.1155/2021/2706789)
- Sarker, S. and Rafe, M. R. 2021. Formulation development of nifedipine through Nanotechnology: a comprehensive review. Pharmaceutical Nanotechnology 9(4), pp. 262-270. (10.2174/2211738509666210707162155)
2020
- Hossain, M. F. et al. 2020. COVID-19 outbreak: pathogenesis, current therapies, and potentials for future management. Frontiers in Pharmacology 11, article number: 563478. (10.3389/fphar.2020.563478)
2018
- Sarker, S., Ali, M. A., Barman, R. K., Noguchi, S., Iwao, Y., Itai, S. and Wahed, M. I. I. 2018. Preparation and antidiabetic effect of orally administered Nifedipine-loaded solid lipid nanoparticles in fructose-induced diabetic rats. Pharmacology & Pharmacy 9(10), article number: 457. (10.4236/pp.2018.910035)
Erthyglau
- Anik, A. H., Proma, F. A., Saha, P. and Sarker, S. 2024. Tegoprazan as a new remedy for gastrointestinal diseases in comparison with its therapeutic predecessors: A mini-review. Current Drug Research Reviews 16(1), pp. 11-17. (10.2174/2589977515666230428140741)
- Sarker, J., Das, P., Sarker, S., Roy, A. K. and Momen, A. Z. M. R. 2021. A review on expression, pathological roles, and inhibition of TMPRSS2, the serine protease responsible for SARS-CoV-2 spike protein activation. Scientifica 2021(1) (10.1155/2021/2706789)
- Sarker, S. and Rafe, M. R. 2021. Formulation development of nifedipine through Nanotechnology: a comprehensive review. Pharmaceutical Nanotechnology 9(4), pp. 262-270. (10.2174/2211738509666210707162155)
- Hossain, M. F. et al. 2020. COVID-19 outbreak: pathogenesis, current therapies, and potentials for future management. Frontiers in Pharmacology 11, article number: 563478. (10.3389/fphar.2020.563478)
- Sarker, S., Ali, M. A., Barman, R. K., Noguchi, S., Iwao, Y., Itai, S. and Wahed, M. I. I. 2018. Preparation and antidiabetic effect of orally administered Nifedipine-loaded solid lipid nanoparticles in fructose-induced diabetic rats. Pharmacology & Pharmacy 9(10), article number: 457. (10.4236/pp.2018.910035)
Bywgraffiad
2023: Dechreuodd PhD yn yr Ysgol Fferylliaeth a Gwyddorau Fferyllol, Prifysgol Caerdydd, Caerdydd, y DU gydag Ysgoloriaeth PhD y Gymanwlad
2017 (Gorffennaf): Ymunodd â Phrifysgol Jagannath yn Bangladesh fel darlithydd
2017: Ymunodd â Phrifysgol Ryngwladol Dhaka fel darlithydd
2016: Cwblhau M.Pharm. gyda thesis ar sefydlu system cyflenwi cyffuriau (nanoronynnau lipid solet) ar gyfer nifedipine
2014: B.Pharm wedi'i gwblhau.
Proffiliau:
ResearchGate: https://www.researchgate.net/profile/Sabarni-Sarker
Google Scholar: https://scholar.google.com/citations?user=B2U3QusAAAAJ&hl=en&oi=ao
Orcid: https://orcid.org/0000-0002-7734-7219
Anrhydeddau a dyfarniadau
2023: Ysgoloriaeth PhD y Gymanwlad
2015: Cymrodoriaeth Gwyddoniaeth a Thechnoleg Genedlaethol (NST) Bangladesh ar gyfer traethawd ymchwil Meistr
